Equillium, a Phase 1 biotech developing monoclonal antibody therapies for aGVHD & cGVHD, announced terms for its IPO on Tuesday.
The La Jolla, CA-based company plans to raise $70 million by offering 4.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Equillium would command a fully diluted market value of $252 million.
Equillium was founded in 2017 and plans to list on the Nasdaq under the symbol EQ. Jefferies, Leerink Partners and Stifel are the joint bookrunners on the deal. It is expected to price during the week of October 8, 2018.
